{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:18:19Z","timestamp":1791926299479,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.tips.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:23:31Z","timestamp":1683041011000},"page":"394-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Omaveloxolone (SkyclarysTM) for patients with Friedreich\u2019s ataxia"],"prefix":"10.1016","volume":"44","author":[{"given":"Sharadha","family":"Dayalan Naidu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-9859","authenticated-orcid":false,"given":"Albena T.","family":"Dinkova-Kostova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2023.03.005_bb0005","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.03.005_bb0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/np100826q","article-title":"New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress","volume":"74","author":"Sporn","year":"2011","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.tips.2023.03.005_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122942","article-title":"RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-Inflammatory activity","volume":"10","author":"Probst","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2023.03.005_bb0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1042\/BST20150003","article-title":"The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics","volume":"43","author":"Dinkova-Kostova","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.tips.2023.03.005_bb0025","doi-asserted-by":"crossref","first-page":"11624","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.03.005_bb0030","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1038\/s41598-018-26269-9","article-title":"C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape","volume":"8","author":"Dayalan Naidu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2023.03.005_bb0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/brain\/awy071","article-title":"KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy","volume":"141","author":"Shekh-Ahmad","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.tips.2023.03.005_bb0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich's ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.tips.2023.03.005_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2023.03.005_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich's ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:14:30Z","timestamp":1759050870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614723000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0165614723000652"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2023.03.005","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omaveloxolone (SkyclarysTM) for patients with Friedreich\u2019s ataxia","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}